Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon

British Journal of Pharmacology

Volumn 122, Issue 2, 1997, Pages 265-268

  Mackness, Bharti ^a   Mackness, Michael I ^a   Arrol, Sharon ^a   Turkie, Wajdi ^a   Durrington, Paul N ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Gulf War Syndrome; OP intoxication; Paraoxonase; PON1

Indexed keywords

ARYLESTERASE; ORGANOPHOSPHATE PESTICIDE; PARAOXON;

ARTICLE; ENZYME ACTIVITY; ENZYME POLYMORPHISM; HUMAN; HUMAN CELL; INTOXICATION; NORMAL HUMAN; PERSIAN GULF SYNDROME; PRIORITY JOURNAL;

ADULT; ARTERIOSCLEROSIS; ARYLDIALKYLPHOSPHATASE; ESTERASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSECTICIDES; MALE; MIDDLE AGED; PARAOXON; POLYMORPHISM, GENETIC;

EID: 0030827926     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701390     Document Type: Article

References (23)

1. ABBOTT, C.A., MACKNESS, M.I., KUMAR, S., BOULTON, A.J.M. & DURRINGTON, P.N. (1995). Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol., 15, 1812-1818.
2. ADKINS, S., GAN, K.N., MODY, M. & LA DU, B.N. (1993). Molecular basis for the polymorphic forms of human serum paraoxonase/ arylesterase: glutamine or arginine at position 191, for the respective A or B alloenzymes. Am. J. Hum. Genet., 52, 598-608.
3. BLATTER-GARIN, M-C., ABBOTT, C., MESSMER, S., MACKNESS, M.I., DURRINGTON, P.N., POMETTA, D. & JAMES, R.W. (1994). Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentration. Biochem. J., 304, 549-554.
4. BLATTER-GARIN, M-C., JAMES, R.W., DUSSOIX, P., BLANCHÉ H., PASSA, P., FROGUEL, P. & RUIZ, J. (1997). Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of the enzyme. J. Clin. Invest., 99, 62-66.
5. COSTA, L.G. & MANZO, L. (1995). Biochemical markers of neurotoxicity: research strategies and epidemiological applications. Toxicol. Letts., 77, 137-144.
6. DAVIES, H.G., RICHTER, R.J., KEIFER, M., BROOMFIELD, C.A., SOWALLA, J. & FURLONG, C.E. (1996). The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman und sarin. Nature Genetics, 14, 334-336.
7. HALEY, R.W., HOM, J., ROLAND, P.S., BRYAN, W.W., VAN NESS, P.C. & BOUTE, F.J. (1997a). Evaluation of neurologic function in Gulf War Veterans. A blinded case-control study. J. Am. Med. Assoc., 277, 223-230.
8. HALEY, R.W. & KURT, T.L. (1997). Self-reported exposure to neurotoxic chemical combinations in the Gulf War. A cross-sectional epidemiologic study. J. Am. Med. Assoc., 277, 231-237.
9. HALEY, R.W., KURT, T.L. & HOM, J. (1997b). Is there a Gulf War Syndrome? Searching for syndromes by factor analysis or symptoms. J. Am. Med. Assoc., 277, 215-222.
10. HUMBERT, R., ADLER, D.A., DISTECHE, C.M., HASSETT, C., OMIECINSKI, C.J. & FURLONG, C.E. (1993). The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genetics, 3, 73-70.
11. LA DU, B.N. (1992). Human serum paraoxonase arylesterase. In Pharmacogenetics of Drug Metabolism, ed. Kalow, W. pp.51-91. New York: Pergamon Press.
12. LA DU, B.N. (1996). Structural and functional diversity of paraoxonase. Nature Med., 2, 1186-1187.
13. MACKNESS, M.I (1989). 'A'-Esterases - Enzymes looking for a role? Biochem. Pharmacol., 38, 385-390.
14. MACKNESS, M.I., ARROL, S., ABBOTT, C.A. & DURRINGTON, P.N. (1993). Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis, 104, 129-135.
15. MACKNESS, M.I., ARROL, S. & DURRINGTON, P.N. (1991a). Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Letts, 286, 152-154.
16. MACKNESS, M.I., ARROL, S., MACKNESS, B. & DURRINGTON, P.N. (1997). The alloenzymes of paraoxonase determine the effectiveness of high-density lipoprotein in protecting low density lipoprotein against lipid-peroxidation. Lancet, 349, 851-852.
17. MACKNESS, M.I., HARTY, D., BHATNAGAR, D., WINOCOUR, P.H., ARROL, S., ISHOLA, M. & DURRINGTON, P.N. (1991b). Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis, 86, 193-199.
18. MACKNESS, M.I., MACKNESS, B., DURRINGTON, P.N., CONNELLY, P.W. & HEGELE, R.A. (1996). Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol., 7, 69-76.
19. NEVIN, D.N., ZAMBON, A., FURLONG, C.E., RICHTER, R.J., HUMBERT, R., HOKANSON, J.E. & BRUNZELL, J.D. (1996). Paraoxonase genotypes, lipoprotein lipase activity and HDL. Arterioscler. Thromb. Vasc. Biol., 16, 1243-1249.
20. THE IOWA PERSIAN GULF STUDY GROUP. (1997). Self-reported illness and health status among Gulf War veterans. A population based study. J. Am. Med. Assoc., 277, 238-245.
21. WATSON, A.D., BERLINER, J.A., HAMA, S.Y., LA DU, B.N., FAULT, K.F., FOGELMAN, A.M. & NAVAB, M. (1995). Protective effect of high density lipoprotein associated paraoxonase - inhibition of the biological activity of minimally oxidised low-density lipoprotein. J. Clin. Invest., 96, 2882-2891.
22. WORLD HEALTH ORGANIZATION. (1986). Informal Consultation on Planning Strategy for the Prevention of Pesticide Poisoning, Geneva, 25-29 November 1995. WHO/VBC/86.926, Geneva: WHO.
23. WORLD HEALTH ORGANIZATION. (1990). Public Health Impact of Pesticides Used in Agriculture, Geneva: WHO.